Organization | Grupo Argentinode Tratamiento

Grupo Argentinode Tratamiento Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

1990

NCT00002499

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

1995

Timeline

NOW

Now

Alternative names

GATLA, Argentina | Grupo Argentino de Tratamiento de la Leucemia Aguda

Active Ingredients

Drugs in Phase 4 Trials (2)

urea (2 trials)

vincristine (oncovin) (2 trials)

Drugs in Phase 3 Trials (5)

asparaginase (elspar) (1 trial)

cytarabine (cytosar-u) (1 trial)

daunorubicin (cerubidine) (1 trial)

naltrexone (revia) (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial APIs: 7